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BAckground: In Mexico breast cancer reported an incidence of 13,939 cases 
and 5,217 mortality cases in 2008. Between 40-50% of those cases are diagnosed 
in stages III and IV. oBjectives: The aim of this study was to assess a cost-effec-
tiveness analysis for the use of fulvestrant 500mg as a therapy for postmenopausal 
women with locally advanced or metastatic breast cancer with ER+ receptor and 
prior progression on endocrine therapy, from Public Health Sector perspective in 
Mexico. Methods: A cost-effectiveness analysis was performed using a Markov 
model with a time horizon of 1 and 5 years according to a prior economic evalua-
tion and based on the results from CONFIRM study. Two cohorts of treatment were 
compared; Cohort A contemplates the addition of fulvestrant to the standard treat-
ment and Cohort B the standard treatment. The effectiveness was measured as Life 
years Gained (LY). The use of resources was determined from the clinical practice 
in Mexico and costs were obtained from institutional sources. results: The ICER 
per LY for 1 year time horizon was $9,609 for Cohort A versus Cohort B. The fifth 
year implies an ICER of $6,581, being in both cases an ICER below the willingness 
to pay in Mexico (1 GDP: $10,000USD). conclusions: Based on the findings the 
use of fulvestrant is a cost-effective strategy that provides a longer period of stable 
disease, an improvement in LY, diminish the use of chemotherapy and optimize 
institutional resources.
PCN113
AssessmeNt Cost-effeCtiveNess of PegfilgrAstim ANd filgrAstim iN 
PediAtriC PAtieNts with solid tumors
Medina Barajas F.P.1, Sánchez Zubieta F.2, Islas Carbajal M.C.3, Pardo Zepeda M.1,  
Ramírez Urenda X.2, Rincón Sánchez A.R.3
1Universidad de Guadalajara, Guadalajara, Mexico, 2Hospital Civil de Guadalajara, Guadalajara, 
Mexico, 3CUCS, Universidad de Guadalajara, Guadalajara, Mexico
oBjectives: Evaluate the cost- effectiveness of pegfilgrastim compared with fil-
grastim relationship in preventing febrile neutropenia in pediatric patients with 
solid tumors. Methods: Retrospective cohort study from 2012 to 2014, and was 
made micro-cost technic. Records of pediatric patients diagnosed with solid tumors 
receiving pegfilgrastim and filgrastim post-chemotherapy for prevention of febrile 
neutropenia were evaluated. Febrile neutropenia is considered as an event with 
absolute neutrophil count less than 1000 cells per milliliter blood and fever ≤ 38.2°C. 
This study adheres to the principles of the Declaration of Helsinki, followed good 
clinical practices and has been approved by Hospital bioethics committee. results: 
120 and 152 cases of pegfilgrastim and filgrastim respectively were included. The 
mean age was 9 years, 63 % male and 47 % female. The absolute neutrophil count 
was 6,204 with pegfilgrastim and filgrastim 2,332. Filgrastim was more effective 
cost $ 1195 pesos per thousand neutrophils, in cases where lower doses were 
administered to 200 micrograms per maximum 7 days. The cost-effectiveness of 
pegfilgrastim was $ 2,484 per thousand neutrophils, reaching a cost effective advan-
tage in cases of patients over 40 kilos would require 7 to 14 doses of filgrastim. No 
significant differences in the effectiveness of pegfilgrastim and filgrastim in post-
chemotherapy preventing neutropenia were observed. conclusions: Filgrastim 
maintains effective cost advantage over pegfilgrastim when the dose is less than 
200 micrograms in a treatment period of at least 7 days
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oBjectives: A randomized clinical study compare effects of pre-operative eicosap-
entaenoic acid enriched oral nutritional supplement (EPA-ONS) along with 5-weeks 
radio-chemotherapy to 5-weeks radio-chemotherapy only on survival and quality 
of life and safety had been completed and the results were published elsewhere. 
This abstract aimed evaluate cost effectiveness of 5-week EPA ONS usage com-
pared to no nutritional supplement in terms of survival. Methods: A total 80 colo-
rectal carcinoma patients had been randomized to 5-week radio-chemotherapy 
(FUFA+EBRT)+EPA ONS (2 package per day) or radio-chemotherapy (FUFA+EBRT) 
only equally by stratifying age, gender, nutritional status and radiotherapy method. 
In study time horizon, survival was evaluated by Kaplan Maier estimator and expo-
nential parametric regression model (best fitting model based on AIC-BIC) was used 
to extrapolate 10-year survival. Since patients’ characteristics, treatment modalities 
and other procedures were reported to be similar among groups, only cost of EPA 
ONS was taken into cost-analysis which is prepared from perspective of reimburse-
ment institute in Turkey. results: Mean (95% confidence interval) survival time 
was 6.8(6.3-7.3) and 5.5(4.6-6.4) years in EPA-ONS + radio-chemotherapy and radio-
chemotherapy only groups, respectively. Five week EPA-ONS costs 224.6 USD/per 
patient. Incremental cost effectiveness ratio (ICER) for in study period was 234.4 
USD per life-year gained; when 10-year survival model was used ICER was 97.5 USD 
per life-year gained. conclusions: Survival analysis revealed that preoperative 
EPA-ONS usage along with radio-chemotherapy prolonged overall survival. EPA-
ONS appears to be a cost-effective concomitant treatment of radio-chemotherapy 
in patient with colorectal carcinoma.
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oBjectives: To estimate the potential public health impact of a 9-valent HPV 
(human papillomavirus) vaccine (HPV9) in Japan in preventing HPV-related dis-
We developed a decision model comparing IHC/MSI tumor tissue testing (IHC/
MSI), followed by targeted sequencing of the suspected gene to two hypothetical 
universal screening strategies: (1) NGS as a reflex test to IHC/MSI testing if these 
tests suggest a protein abnormality; (3) use of a NGS gene panel in all patients 
with CRC. Outcomes measured were life-years gained, quality adjusted life years 
(QALY) gained, and costs, Sensitivity analyses were conducted to assess uncer-
tainty. results: Compared to the reference strategy, the price per QALY gained 
was $196,000 for universal NGS gene panel testing. When using NGS gene panel as 
a reflex strategy to abnormal IHC/MSI, the price per QALY was $71,000. The most 
influential variables in the one-way sensitivity analysis were the number of relatives 
tested, the prevalence of Lynch syndrome in CRC patients and the cost of CRC sur-
veillance in relatives with Lynch syndrome detected. conclusions: Use of NGS in 
all colorectal cancer patients to detect inherited cancer and inform family members 
is unlikely to be cost-effective despite the lower per base pair sequencing cost of 
NGS. However, NGS may be cost-effective when used as a complement to tumor-
tissue testing strategies. Further studies are needed to validate these findings.
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oBjectives: High-risk, non-muscle-invasive bladder cancer (NMIBC) is heteroge-
neous in its presentation, resulting in patient subpopulations with diverse treat-
ment options. A comprehensive model estimating costs and health outcomes 
with various NMIBC treatment strategies is needed for diverse patient subpopula-
tions. Methods: A Markov model simulating patient outcomes was developed 
based on published treatment guidelines. Health states encompass high-risk NMIBC, 
tumor-free, muscle-invasive progression (MIP), and metastasis. Four patient popula-
tions were considered: (1) high-risk T1 or Ta tumors; (2) Carcinoma in situ (Cis) only; 
(3) high-risk T1/Ta tumors with concomitant Cis; (4) general NMIBC population with 
high-risk T1/Ta tumors and/or Cis. Treatment options include trans-urethral resec-
tion (TUR) and adjuvant intravesical bacillus Calmette-Guérin (BCG), mitomycin C 
(MMC) or valrubicin for populations (1), (3) and (4), or intravesical treatment alone for 
population (2). The model assesses treatments as first- or second-line, or as alterna-
tives for patients intolerant of or refractory to other treatment. Radical cystectomy 
is performed after MIP or repeated treatment failure. Response (in patients with Cis) 
and recurrence rates and percentages of BCG-intolerant/refractory patients were 
estimated from the literature. Costs were obtained from publicly available sources. 
The model was validated against published epidemiology and cost data. results: 
The lifetime cost per person of treating high-risk T1/Ta patients with BCG was within 
20% of costs estimated in published economic models. The lifetime cost per person 
of treating BCG-intolerant/refractory Cis patients with valrubicin was estimated to 
be 45% higher than for cystectomy. Adverse event costs for the general high-risk 
NMIBC population treated with BCG account for 17% of the total treatment cost com-
pared with 5% for MMC. Approximately 40% and 15% of patients treated with BCG 
eventually undergo cystectomy and MIP, respectively. conclusions: This validated 
model can be used to estimate costs and health outcomes associated with existing 
treatment strategies as well as the cost-effectiveness of novel intravesical therapies.
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oBjectives: Fabulous advance in treatment of NSCLC has been made since the late 
1990s, remarkably with the development of targeted drugs such as bevacizumab 
(BEV). Despite of the proved effectiveness and safety of BEV in treatment of NSCLC, 
the high price of drug caused obstacles in using drugs in clinical practice. The cost-
effectiveness of BEV has been evaluated in many countries. However until now there 
isn’t any relevant study has been evaluated. This is the aim of this study. Methods: 
A Markov model has been developed to evaluate the cost-effectiveness of beva-
cizumab in treatment of NSCLC with 3 Markov stages, including stable disease, 
progressive disease and death. The model has a cycle length of 1 year with the time 
horizon of life time. The population of 1000 patients patients, entering the model 
in the SD state, has been evaluated to assess the cost of effectiveness of different 
treatment regimens. The transition rates have been retrieved from clinical trials. The 
prices of drugs and medical services have been retrieved from relevant price-lists of 
major hospitals in Vietnam. The sensitivity analysis has been conducted to evaluate 
the sensitivity of model. results: The cost of BCP and PC regimen for treatment 
of NSCLC accounts for 5,979,573,560 VND and 992,767,115 with the QALY of 10.43 
and 7.24, respectively. The CER of BCP regimens for treatment of NCSLC accounts 
for 573,199,170 VND, which is around 4 times higher than that of PC regimen. The 
ICER of BCP regimen versus PC regimen in treatment of NSCLC accounts for around 
1.56 billion VND, which is around 20 times higher than the willingness-to-pay of 
Vietnam (60 million VND). conclusions: Due to the high cost of drug, combina-
tion of bevacizumab in the PC regimen in treatment of NSCLC is considered not 
cost-effectiven in Vietnam.
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